{
  "id": 10418119,
  "title": "18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.",
  "url": "https://urgent.news/2026/09/28/18-of-21-analysts-still-think-alnylam-stock-is-a-buy-heres-why-theyre",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-28T09:23:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/09/28/18-of-21-analysts-still-think-alnylam-stock-is-a-b/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": null,
  "summary": "Wall Street expects an even bigger rebound for this beaten-down biotech stock.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.",
        "url": "https://urgent.news/2026/09/28/18-of-21-analysts-still-think-alnylam-stock-is-a-buy-heres-why-theyre-10419210",
        "published": "2026-09-28T09:43:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}